GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (FRA:23J0) » Definitions » Valuation Rank

ProMIS Neurosciences (FRA:23J0) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is ProMIS Neurosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

ProMIS Neurosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (FRA:23J0) » Definitions » Valuation Rank
Comparable Companies
NRSN JUNS FNCH ENLV IGC CARA LGVN PASG MLEC ABP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
PMN:USA 23J0:Germany
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
Website
https://www.promisneurosciences.com
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.